Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Boston Scientific (BSX)

NYSE: BSX · Medical Devices · Marlborough, MA

Our rating: Positive

Positive reaffirmed at $43.50, high conviction, November 3, 2026.

Breaks if: Revenue growth decelerates below ten percent year-over-year in either of the next two quarterly filings, or reported free cash flow on a trailing twelve-month basis falls below two-point-five billion dollars — either outcome would indicate the operational momentum underpinning this call has broken and the Positive view should be revisited.

Key figures

Market value$60.8B
Revenue, last 12 months$21.1B
Net income, last 12 months$3.5B
Free cash flow, last 12 months$3.3B
Price to earnings17.4×
Free cash flow yield5.5%
Dividend yield0.0%
Operating margin18.7%
Return on equity14.3%
Beta to the S&P 5000.55
Volatility, annualized30.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$5.1B1.4%$0.40$868M
June 30, 2026$5.4B7.5%$0.61$1.3B
March 31, 2026$5.2B11.6%$0.90$171M
December 31, 2025$5.3B15.9%$0.45$1.0B
September 30, 2025$5.1B20.3%$0.51$1.2B
June 30, 2025$5.1B22.8%$0.53$1.1B
March 31, 2025$4.7B20.9%$0.45$354M
December 31, 2024$4.6B22.4%$0.38$1.2B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.